Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Investcorp-Tages UCITS platform launches new Selwood fund managed by Karim Moussalem
-
Cardiol Therapeutics (CRDL) Announces At-The-Market Equity Offering Program
-
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
-
PTC Therapeutics (PTCT) Appoints Alethia Young to its Board
-
Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
-
"Encourage Investors to Acquire Shares" - Cantor Fitzgerald Reiterates Overweight Rating on SeaSpine Holdings (SPNE) with $21 Price Target
-
BioReference "Collaboration Further Validates OVA1Plus Offering" - Cantor Fitzgerald Bullish on Aspira Women’s Health (AWH) with Overweight Rating and $6 Price Target
-
Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting
-
Rekor Systems to Present at Cantor Fitzgerald Technology ESG Conference, June 27-29, 2022, in Palo Alto, CA
-
Enovix to Participate in Upcoming Investor Conferences
-
Enovix to Participate in Upcoming Investor Conferences
-
Cantor Fitzgerald Reiterates Overweight Rating, $335 Price Target on Eli Lilly (LLY)
-
BGC Partners (BGCP) Appoints Jason W. Hauf as CFO
-
BGC Partners Appoints Jason W. Hauf as Chief Financial Officer
-
STRATUM Data is "Clearly Good News... Could Drive Stock Higher" - Cantor Fitzgerald Bullish on Arcutis Biotherapeutics (ARQT) Following Phase 3 Readout
-
NuScale to Attend Upcoming Investor Conferences
-
"Positive Zotatifin Data Supports An Opportunity In Breast Cancer" - Cantor Fitzgerald Bullish on eFFECTOR Therapeutics (EFTR) With Overweight Rating, $50 Price Target
-
Form 4 Cantor Fitzgerald Income For: Jun 01 Filed by: LUTNICK HOWARD W
-
Form SC 13G Northern Star Investment Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Northern Star Investment Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Shelter Acquisition Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Concord Acquisition Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G SVF Investment Corp. 2 Filed by: CANTOR FITZGERALD SECURITIES
-
Form SC 13G Khosla Ventures Acquisit Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald Starts ObsEva (OBSV) at Overweight
-
CPS Solutions, LLC Announces Acquisition of Trellis Rx, LLC, Offering End-To-End Suite of Products and Solutions Across Inpatient, Outpatient & Specialty Pharmacy
-
CPS Solutions, LLC Announces Acquisition of Trellis Rx, LLC, Offering End-To-End Suite of Products and Solutions Across Inpatient, Outpatient & Specialty Pharmacy
-
Cantor Fitzgerald Reiterates Overweight Rating, $34 Price Target on Nyxoah SA (NYXH)
-
UPDATE: Cantor Fitzgerald Starts Ocugen, Inc. (OCGN) at Overweight
-
UPDATE: Cantor Fitzgerald Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight
-
Form 8-K Cantor Fitzgerald Income For: Jun 01
-
Selina to Participate in Upcoming Conferences in June 2022
-
UPDATE: Cantor Fitzgerald Starts Gracell Biotechnologies Inc (GRCL) at Overweight
-
Form SC 13G Elliott Opportunity II Filed by: CANTOR FITZGERALD SECURITIES
-
Canopy Growth (WEED:CN) (CGC) PT Lowered to Cdn$6.75 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Assumes Aziyo Biologics Inc. (AZYO) at Overweight, PT Lowered to $12
-
MSP Recovery Reaffirms Revenue Guidance Originally Set Forth in Prior Financial Models and Announces Substantial Business Expansion Through Development of Additional Revenue Streams, Monetization of A
-
MSP Recovery Reaffirms Revenue Guidance Originally Set Forth in Prior Financial Models and Announces Substantial Business Expansion Through Development of Additional Revenue Streams, Monetization of A
-
ECARX to Go Public in $3.82 Billion Merger with COVA Acquisition Corp. (COVA)
-
ECARX to Go Public in $3.82 Billion Merger with COVA Acquisition Corp., Accelerating Development of Next-Generation Automotive Intelligence
-
ShotSpotter Sets June 2022 Financial Conference Schedule
-
Chinook Therapeutics (KDNY) Prices $105M Public Offering at $14/sh
-
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
-
Chinook Therapeutics (KDNY) Announces Proposed Stock Offering, Size not Disclosed
-
Chinook Therapeutics Announces Proposed Public Offering
-
"VTAMA Has Blockbuster Potential" - Cantor Fitzgerald Bullish on Roivant Sciences (ROIV) Following Dermavant’s Drug Approval
-
Enovix to Participate in Upcoming Investor Conferences
-
Enovix to Participate in Upcoming Investor Conferences
-
Cantor Fitzgerald Starts Similarweb Ltd (SMWB) at Neutral
-
Cantor Fitzgerald Assumes Rapt Therapeutics (RAPT) at Overweight

